BOSTON--(BUSINESS WIRE)--
Shareholders of Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today elected Alan
M. Garber, M.D., Ph.D. as an independent member of its board of
directors. Dr. Garber is Provost of Harvard University, the Mallinckrodt
Professor of Health Care Policy at Harvard Medical School, a Professor
of Economics in the Faculty of Arts and Sciences, a Professor of Public
Policy in the Harvard Kennedy School of Government, and a Professor in
the Department of Health Policy and Management in the Harvard T.H. Chan
School of Public Health.
"We are delighted that Alan is joining the Vertex Board. He brings both
his deep experience as an academic physician as well as his expertise in
health economics and the complexities of our healthcare system to
Vertex," said Jeffrey
Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer
of Vertex. "His insights and expertise will be invaluable as we continue
to deliver on our mission of bringing transformative medicines to more
people with cystic fibrosis and other serious diseases."
"I am pleased to join the board of an organization that endeavors to
discover and deliver new medicines to treat life-threatening diseases,"
said Dr. Garber. "As a physician-researcher, I look forward to working
together to improve the lives of people around the world."
Prior to joining Harvard in 2011, Dr. Garber was the Henry J. Kaiser Jr.
Professor, a Professor of Medicine, and a Professor (by courtesy) of
Economics, Health Research and Policy, and of Economics in the Graduate
School of Business at Stanford University. He is a member of the
National Academy of Medicine, the American Academy of Arts and Sciences,
the American Society of Clinical Investigation, the Association of
American Physicians and the Board on Science, Technology, and Economic
Policy at the National Academies. Dr. Garber is also a Fellow of the
American College of Physicians and the Royal College of Physicians and a
Research Associate with the National Bureau of Economic Research. He
also has served as a member of the National Advisory Council on Aging at
the National Institutes of Health, the Board of Health Advisers of the
Congressional Budget Office and Chair of the Medicare Evidence
Development and Coverage Advisory Committee at the Centers for Medicare
and Medicaid Services.
Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D. in
Economics from Harvard University, as well as an M.D. with research
honors from Stanford University.
About Vertex
Vertex is a global biotechnology company that
aims to discover, develop and commercialize innovative medicines so
people with serious diseases can lead better lives. In addition to our
clinical development programs focused on cystic fibrosis, Vertex has
more than a dozen ongoing research programs aimed at other serious and
life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and
development sites and commercial offices in the United States, Europe,
Canada and Australia. For seven years in a row, Science magazine
has named Vertex one of its Top Employers in the life sciences. For
additional information and the latest updates from the company, please
visit www.vrtx.com.
(VRTX-GEN)
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608006237/en/
Vertex Pharmaceuticals Incorporated
Investors:
Michael
Partridge, +1 617-341-6108
or
Eric Rojas, +1 617-961-7205
or
Zach
Barber, +1 617-341-6470
or
Media:
mediainfo@vrtx.com
North
America: +1 617-341-6992
or
Europe & Australia: +44 20 3204
5275
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
